The complexity in treatment of patients in shock

Sponsored by Abiomed

Anchorperson: G. Tarantini

Discussants: A. Chieffo, N. Mangner, K. Mashayekhi

Summary

This session is essential for those looking to analyze and discuss the findings of the DanGer shock randomized trial, explore the latest evidence in the ACS field such as Horizon, and implement evidence-based practices in peri-procedural planning, execution, drug administration, and weaning strategies to optimize outcomes in acute myocardial infarction complicated by cardiogenic shock, since the session presents the latest data on ECLS and Impella, compares both in shock management, and offers insights on improving survival rates in shock patients, including the latest data on revascularization completeness with percutaneous ventricular assist devices versus IABP.

Learning Objectives

To learn the latest data on ECLS, Impella and comparison of both in shock
To learn on how to improve survival of shock patients
To see latest data on revascularisation completeness with percutaneous ventricular assist devices vs IABP